

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/ HRS Guideline for the Management of Patients With Atrial Fibrillation

Developed in Collaboration With the Society of Thoracic Surgeons

© American College of Cardiology Foundation and American Heart Association



Citation

This slide set is adapted from the **2019 AHA/ACC/HRS FOCUSED UPDATE OF THE 2014 AHA/ACC/HRS GUIDELINE FOR THE MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION**. Published on **January 28, 2019**, available at: *Journal of the American College of Cardiology* [(insert full link)] and *Circulation* [(insert full link)]

The full-text guidelines are also available on the following Web sites: ACC (www.acc.org) and AHA (professional.heart.org)



Writing Committee

Craig T. January, MD, PhD, FACC, *Chair*
L. Samuel Wann, MD, FACC, FAHA, *Vice Chair*

Hugh Calkins, MD, FACC, FAHA, FHRS*†

Lin Y. Chen, MD, MS, FACC, FAHA, FHRS†

Joaquin E. Cigarroa, MD, FACC‡

Joseph C. Cleveland, Jr, MD, FACC*§

Patrick T. Ellinor, MD, PhD*†

Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA*||

Hugh Calkins, MD, FACC, FAHA, FHRS*†

Lin Y. Chen, MD, MS, FACC, FAHA, FHRS†

Michael E. Field, MD, FACC, FAHA, FHRS ||

Karen L. Furie, MD, MPH, FAHA ||

Paul A. Heidenreich, MD, FACC, FAHA¶

Katherine T. Murray, MD, FACC, FAHA, FHRS ||

Julie B. Shea, MS, RNCS, FHRS* ||

Cynthia M. Tracy, MD, FAHA* ||

Michael E. Field, MD, FACC, FAHA, FHRS ||

Karen L. Furie, MD, MPH, FAHA ||

Clyde W. Yancy, MD, MACC, FAHA ||

‡ACC/AHA Task Force on Clinical Practice Guidelines Liaison. ||ACC/AHA Representative. †HRS Representative. §STS Representative. ¶ACC/AHA Task Force on Performance Measures Representative.



Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)

CLASS (STRENGTH) OF RECOMMENDATION	
CLASS I (STRONG)	Benefit >>> Risk
Suggested phrases for writing recommendations: <ul style="list-style-type: none"> Is recommended Is indicated/useful/effective/beneficial Should be performed/administered/other Comparative-Effectiveness Phrases†: <ul style="list-style-type: none"> Treatment/strategy A is recommended/indicated in preference to treatment B Treatment A should be chosen over treatment B 	
CLASS IIa (MODERATE)	Benefit >> Risk
Suggested phrases for writing recommendations: <ul style="list-style-type: none"> Is reasonable Can be useful/effective/beneficial Comparative-Effectiveness Phrases†: <ul style="list-style-type: none"> Treatment/strategy A is probably recommended/indicated in preference to treatment B It is reasonable to choose treatment A over treatment B 	
CLASS IIb (WEAK)	Benefit ≥ Risk
Suggested phrases for writing recommendations: <ul style="list-style-type: none"> May/might be reasonable May/might be considered Usefulness/effectiveness is unknown/unclear/uncertain or not well established 	
CLASS III: No Benefit (MODERATE)	Benefit = Risk
<i>(Generally, LOE A or B use only)</i> Suggested phrases for writing recommendations: <ul style="list-style-type: none"> Is not recommended Is not indicated/useful/effective/beneficial Should not be performed/administered/other 	
CLASS III: Harm (STRONG)	Risk > Benefit
Suggested phrases for writing recommendations: <ul style="list-style-type: none"> Potentially harmful Causes harm Associated with excess morbidity/mortality Should not be performed/administered/other 	

LEVEL (QUALITY) OF EVIDENCE‡	
LEVEL A	<ul style="list-style-type: none"> High-quality evidence‡ from more than 1 RCT Meta-analyses of high-quality RCTs One or more RCTs corroborated by high-quality registry studies
LEVEL B-R	(Randomized) <ul style="list-style-type: none"> Moderate-quality evidence‡ from 1 or more RCTs Meta-analyses of moderate-quality RCTs
LEVEL B-NR	(Nonrandomized) <ul style="list-style-type: none"> Moderate-quality evidence‡ from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies Meta-analyses of such studies
LEVEL C-LD	(Limited Data) <ul style="list-style-type: none"> Randomized or nonrandomized observational or registry studies with limitations of design or execution Meta-analyses of such studies Physiological or mechanistic studies in human subjects
LEVEL C-EO	(Expert Opinion) Consensus of expert opinion based on clinical experience

COR and LOE are determined independently (any COR may be paired with any LOE).

A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

† For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

‡ The method of assessing quality is evolving, including the application of standardized, widely used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.

2019 Focused Update on Atrial Fibrillation

Recommendations for Selecting an Anticoagulant Regimen—Balancing Risks and Benefits

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen—Balancing Risks and Benefits		
COR	LOE	Recommendations
I	A	<p>For patients with AF and an elevated CHA₂DS₂-VASc score of 2 or greater in men or 3 or greater in women, oral anticoagulants are recommended.</p> <p>Options include:</p> <ul style="list-style-type: none"> • Warfarin (LOE: A) • Dabigatran (LOE: B) • Rivaroxaban (LOE: B) • Apixaban (LOE: B) or • Edoxaban (LOE: B-R) <p>MODIFIED: This recommendation has been updated in response to the approval of edoxaban, a new factor Xa inhibitor. More precision in the use of CHA₂DS₂-VASc scores is specified in subsequent recommendations. The LOEs for warfarin, dabigatran, rivaroxaban, and apixaban have not been updated for greater granularity as per the new LOE system. (Section 4.1. in the 2014 AF Guideline) The original text can be found in Section 4.1 of the 2014 AF guideline. Additional information about the comparative effectiveness and bleeding risk of NOACs can be found in Section 4.2.2.2.</p>
	B	
	B	
	B	
	B-R	

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen—Balancing Risks and Benefits

COR	LOE	Recommendations
I	A	<p>NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) are recommended over warfarin in NOAC-eligible patients with AF (except with moderate-to-severe mitral stenosis or a mechanical heart valve).</p> <p>NEW: Exclusion criteria are now defined as moderate-to-severe mitral stenosis or a mechanical heart valve. When the NOAC trials are considered as a group, the direct thrombin inhibitor and factor Xa inhibitors were at least noninferior and, in some trials, superior to warfarin for preventing stroke and systemic embolism and were associated with lower risks of serious bleeding.</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits

COR	LOE	Recommendations
I	A	<p>Among patients treated with warfarin, the international normalized ratio (INR) should be determined at least weekly during initiation of anticoagulant therapy and at least monthly when anticoagulation (INR in range) is stable.</p> <p>MODIFIED: “Antithrombotic” was changed to “anticoagulant.”</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits		
COR	LOE	Recommendations
I	B	<p>In patients with AF (except with moderate-to-severe mitral stenosis or a mechanical heart valve), the CHA₂DS₂-VASc score is recommended for assessment of stroke risk.</p> <p>MODIFIED: Exclusion criteria are now defined as moderate-to-severe mitral stenosis or a mechanical heart valve. Patients with AF with bioprosthetic heart valves are addressed in the supportive text. (Section 4.1. in the 2014 AF guideline)</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits		
COR	LOE	Recommendations
I	B	For patients with AF who have mechanical heart valves, warfarin is recommended. MODIFIED: New information is included in the supportive text.

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits		
COR	LOE	Recommendations
I	B	<p>Selection of anticoagulant therapy should be based on the risk of thromboembolism, irrespective of whether the AF pattern is paroxysmal, persistent, or permanent.</p> <p>MODIFIED: “Antithrombotic” was changed to “anticoagulant.”</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits		
COR	LOE	Recommendations
I	B-NR	Renal function and hepatic function should be evaluated before initiation of a NOAC and should be reevaluated at least annually. MODIFIED: Evaluation of hepatic function was added. LOE was updated from B to B-NR. New evidence was added. (Section 4.1. in the 2014 AF Guideline)

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits		
COR	LOE	Recommendations
I	C	<p>In patients with AF, anticoagulant therapy should be individualized on the basis of shared decision-making after discussion of the absolute risks and relative risks of stroke and bleeding, as well as the patient’s values and preferences.</p> <p>MODIFIED: “Antithrombotic” was changed to “anticoagulant.”</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits

COR	LOE	Recommendations
I	C	<p>For patients with atrial flutter, anticoagulant therapy is recommended according to the same risk profile used for AF.</p> <p>MODIFIED: “Antithrombotic” was changed to “anticoagulant.”</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits		
COR	LOE	Recommendations
I	C	<p>Reevaluation of the need for and choice of anticoagulant therapy at periodic intervals is recommended to reassess stroke and bleeding risks.</p> <p>MODIFIED: “Antithrombotic” was changed to “anticoagulant.”</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits

COR	LOE	Recommendations
I	C-EO	<p>For patients with AF (except with moderate-to-severe mitral stenosis or a mechanical heart valve) who are unable to maintain a therapeutic INR level with warfarin, use of a NOAC is recommended.</p> <p>MODIFIED: Exclusion criteria are now defined as moderate-to-severe mitral stenosis or a mechanical heart valve, and this recommendation has been changed in response to the approval of edoxaban. (Section 4.1. in the 2014 AF Guideline)</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits

COR	LOE	Recommendations
Ila	B	<p>For patients with AF (except with moderate-to-severe mitral stenosis or a mechanical heart valve) and a CHA₂DS₂-VASc score of 0 in men or 1 in women, it is reasonable to omit anticoagulant therapy.</p> <p>MODIFIED: Exclusion criteria are now defined as moderate-to-severe mitral stenosis or a mechanical heart valve. (Section 4.1. in the 2014 AF Guideline)</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits		
COR	LOE	Recommendations
IIb	B-NR	<p>For patients with AF who have a CHA₂DS₂-VASc score of 2 or greater in men or 3 or greater in women and who have end-stage chronic kidney disease (CKD; creatinine clearance [CrCl] <15 mL/min) or are on dialysis, it might be reasonable to prescribe warfarin (INR 2.0 to 3.0) or apixaban for oral anticoagulation.</p> <p>MODIFIED: New evidence has been added. LOE was updated from B to B-NR. (Section 4.1. in the 2014 AF Guideline)</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen—Balancing Risks and Benefits

COR	LOE	Recommendations
IIb	B-R	<p>For patients with AF (except with moderate-to-severe mitral stenosis or a mechanical heart valve) and moderate-to-severe CKD (serum creatinine ≥ 1.5 mg/dL [apixaban], CrCl 15 to 30 mL/min [dabigatran], CrCl ≤ 50 mL/min [rivaroxaban], or CrCl 15 to 50 mL/min [edoxaban]) with an elevated CHA₂DS₂-VASc score, treatment with reduced doses of direct thrombin or factor Xa inhibitors may be considered (e.g., dabigatran, rivaroxaban, apixaban, or edoxaban).</p> <p>MODIFIED: Exclusion criteria are now defined as moderate-to-severe mitral stenosis or a mechanical heart valve, and this recommendation has been changed in response to the approval of edoxaban. LOE was updated from C to B-R. (Section 4.1. in the 2014 AF Guideline)</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits		
COR	LOE	Recommendations
IIb	C- LD	<p>For patients with AF (except with moderate-to-severe mitral stenosis or a mechanical heart valve) and a CHA₂DS₂-VASc score of 1 in men and 2 in women, prescribing an oral anticoagulant to reduce thromboembolic stroke risk may be considered.</p> <p>MODIFIED: Exclusion criteria are now defined as moderate-to-severe mitral stenosis or a mechanical heart valve, and evidence was added to support separate risk scores by sex. LOE was updated from C to C-LD. (Section 4.1. in the 2014 AF Guideline)</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits		
COR	LOE	Recommendations
III: No Benefit	C-EO	<p>In patients with AF and end-stage CKD or on dialysis, the direct thrombin inhibitor dabigatran or the factor Xa inhibitors rivaroxaban or edoxaban are not recommended because of the lack of evidence from clinical trials that benefit exceeds risk.</p> <p>MODIFIED: New data have been included. Edoxaban received FDA approval and has been added to the recommendation. LOE was updated from C to C-EO. (Section 4.1. in the 2014 AF Guideline)</p>

Anticoagulation Regimen – Balancing Risks and Benefits

Recommendations for Selecting an Anticoagulant Regimen— Balancing Risks and Benefits

COR	LOE	Recommendations
III: Harm	B-R	<p>The direct thrombin inhibitor dabigatran should not be used in patients with AF and a mechanical heart valve.</p> <p>MODIFIED: Evidence was added. LOE was updated from B to B-R. Other NOACs are addressed in the supportive text. (Section 4.1. in the 2014 AF Guideline)</p>

2019 Focused Update on Atrial Fibrillation

Interruption and Bridging Anticoagulation



Interruption and Bridging Anticoagulation

Recommendations for Interruption and Bridging Anticoagulation		
COR	LOE	Recommendations
I	C	Bridging therapy with unfractionated heparin or low-molecular-weight heparin is recommended for patients with AF and a mechanical heart valve undergoing procedures that require interruption of warfarin. Decisions on bridging therapy should balance the risks of stroke and bleeding.
I	B-R	For patients with AF without mechanical heart valves who require interruption of warfarin for procedures, decisions about bridging therapy (unfractionated heparin or low-molecular-weight heparin) should balance the risks of stroke and bleeding and the duration of time a patient will not be anticoagulated. MODIFIED: LOE was updated from C to B-R because of new evidence. (Section 4.1. in the 2014 AF Guideline)

Interruption and Bridging Anticoagulation

Recommendations for Interruption and Bridging Anticoagulation		
COR	LOE	Recommendations
I	B-NR	<p>Idarucizumab is recommended for the reversal of dabigatran in the event of life-threatening bleeding or an urgent procedure.</p> <p>NEW: New evidence has been published about idarucizumab to support LOE B-NR.</p>
Ila	B-NR	<p>Andexanet alfa can be useful for the reversal of rivaroxaban and apixaban in the event of life-threatening or uncontrolled bleeding.</p> <p>NEW: New evidence has been published about andexanet alfa to support LOE B-NR.</p>

2019 Focused Update on Atrial Fibrillation

Nonpharmacological Stroke Prevention



Percutaneous Approaches to Occlude the LAA

Recommendation for Percutaneous Approaches to Occlude the LAA		
COR	LOE	Recommendation
IIb	B-NR	<p>Percutaneous LAA occlusion may be considered in patients with AF at increased risk of stroke who have contraindications to long-term anticoagulation.</p> <p>NEW: Clinical trial data and FDA approval of the Watchman device necessitated this recommendation.</p>

Cardiac Surgery – LAA Occlusion/Excision

Recommendation for Cardiac Surgery—LAA Occlusion/Excision		
COR	LOE	Recommendation
IIb	B-NR	<p>Surgical occlusion of the LAA may be considered in patients with AF undergoing cardiac surgery, as a component of an overall heart team approach to the management of AF.</p> <p>MODIFIED: LOE was updated from C to B-NR because of new evidence.</p>

2019 Focused Update on Atrial Fibrillation

Rhythm Control

Prevention of Thromboembolism

Recommendations for Prevention of Thromboembolism

COR	LOE	Recommendations
I	B-R	<p>For patients with AF or atrial flutter of 48 hours' duration or longer, or when the duration of AF is unknown, anticoagulation with warfarin (INR 2.0 to 3.0), a factor Xa inhibitor, or direct thrombin inhibitor is recommended for at least 3 weeks before and at least 4 weeks after cardioversion, regardless of the CHA₂DS₂-VASc score or the method (electrical or pharmacological) used to restore sinus rhythm.</p> <p>MODIFIED: The 2014 AF Guideline recommendation for use of warfarin around the time of cardioversion was combined with the 2014 AF Guideline recommendation for NOACs to create a single recommendation. This combined recommendation was updated to COR I/ LOE B-R from COR IIa/LOE C for NOACs in the 2014 AF Guideline on the basis of additional trials that have evaluated the use of NOACs with cardioversion.</p>
I	C	<p>For patients with AF or atrial flutter of more than 48 hours' duration or unknown duration that requires immediate cardioversion for hemodynamic instability, anticoagulation should be initiated as soon as possible and continued for at least 4 weeks after cardioversion unless contraindicated.</p>

Prevention of Thromboembolism

Recommendations for Prevention of Thromboembolism

COR	LOE	Recommendations
I	C-EO	<p>After cardioversion for AF of any duration, the decision about long-term anticoagulation therapy should be based on the thromboembolic risk profile and bleeding risk profile.</p> <p>MODIFIED: The 2014 AF Guideline recommendation was strengthened with the addition of bleeding risk profile to the long-term anticoagulation decision-making process.</p>
IIa	B-NR	<p>For patients with AF or atrial flutter of less than 48 hours' duration with a CHA₂DS₂-VASc score of 2 or greater in men and 3 or greater in women, administration of heparin, a factor Xa inhibitor, or a direct thrombin inhibitor is reasonable as soon as possible before cardioversion, followed by long-term anticoagulation therapy.</p> <p>MODIFIED: Recommendation COR was changed from I in the 2014 AF Guideline to IIa, and LOE was changed from C in the 2014 AF Guideline to B-NR. In addition, a specific CHA₂DS₂-VASc score is now specified.</p>

Prevention of Thromboembolism

Recommendations for Prevention of Thromboembolism		
COR	LOE	Recommendations
IIa	B	For patients with AF or atrial flutter of 48 hours' duration or longer or of unknown duration who have not been anticoagulated for the preceding 3 weeks, it is reasonable to perform transesophageal echocardiography before cardioversion and proceed with cardioversion if no left atrial thrombus is identified, including in the LAA, provided that anticoagulation is achieved before transesophageal echocardiography and maintained after cardioversion for at least 4 weeks.
IIb	B-NR	For patients with AF or atrial flutter of less than 48 hours' duration with a CHA ₂ DS ₂ -VASc score of 0 in men or 1 in women, administration of heparin, a factor Xa inhibitor, or a direct thrombin inhibitor, versus no anticoagulant therapy, may be considered before cardioversion, without the need for postcardioversion oral anticoagulation. MODIFIED: Recommendation LOE was changed from C in the 2014 AF Guideline to B-NR to reflect evidence from 2 registry studies and to include specific CHA ₂ DS ₂ -VASc scores derived from study results.

2019 Focused Update on Atrial Fibrillation

AF Catheter Ablation to Maintain Sinus Rhythm



Catheter Ablation in HF

Recommendation for Catheter Ablation in HF		
COR	LOE	Recommendation
IIb	B-R	<p>AF catheter ablation may be reasonable in selected patients with symptomatic AF and HF with reduced left ventricular (LV) ejection fraction (HFrEF) to potentially lower mortality rate and reduce hospitalization for HF.</p> <p>NEW: New evidence, including data on improved mortality rate, has been published for AF catheter ablation compared with medical therapy in patients with HF.</p>

2019 Focused Update on Atrial Fibrillation

Specific Patient Groups and AF



AF Complicating ACS

Recommendations for AF Complicating ACS		
COR	LOE	Recommendations
I	B-R	<p>For patients with ACS and AF at increased risk of systemic thromboembolism (based on CHA₂DS₂-VASc risk score of 2 or greater), anticoagulation is recommended unless the bleeding risk exceeds the expected benefit.</p> <p>MODIFIED: New published data are available. LOE was updated from C in the 2014 AF Guideline to B-R.</p> <p>Anticoagulation options are described in supportive text.</p>
I	C	<p>Urgent direct-current cardioversion of new-onset AF in the setting of ACS is recommended for patients with hemodynamic compromise, ongoing ischemia, or inadequate rate control.</p>

AF Complicating ACS

Recommendations for AF Complicating ACS

COR	LOE	Recommendations
I	C	Intravenous beta blockers are recommended to slow a rapid ventricular response to AF in patients with ACS who do not display HF, hemodynamic instability, or bronchospasm.
IIa	B-NR	If triple therapy (oral anticoagulant, aspirin, and P2Y ₁₂ inhibitor) is prescribed for patients with AF at increased risk of stroke (based on CHA ₂ DS ₂ -VASc risk score of 2 or greater) who have undergone percutaneous coronary intervention (PCI) with stenting for ACS, it is reasonable to choose clopidogrel in preference to prasugrel. NEW: New published data are available.

AF Complicating ACS

Recommendations for AF Complicating ACS

COR	LOE	Recommendations
IIa	B-R	<p>In patients with AF at increased risk of stroke (based on CHA₂DS₂-VASc risk score of 2 or greater) who have undergone PCI with stenting for ACS, double therapy with a P2Y₁₂ inhibitor (clopidogrel or ticagrelor) and dose-adjusted vitamin K antagonist is reasonable to reduce the risk of bleeding as compared with triple therapy.</p> <p>NEW: New RCT data and data from 2 registries and a retrospective cohort study are available.</p>
IIa	B-R	<p>In patients with AF at increased risk of stroke (based on CHA₂DS₂-VASc risk score of 2 or greater) who have undergone PCI with stenting for ACS, double therapy with P2Y₁₂ inhibitors (clopidogrel) and low-dose rivaroxaban 15 mg daily is reasonable to reduce the risk of bleeding as compared with triple therapy.</p> <p>NEW: New published data are available.</p>

AF Complicating ACS

Recommendations for AF Complicating ACS

COR	LOE	Recommendations
IIa	B-R	<p>In patients with AF at increased risk of stroke (based on CHA₂DS₂-VASc risk score of 2 or greater) who have undergone PCI with stenting for ACS, double therapy with a P2Y₁₂ inhibitor (clopidogrel) and dabigatran 150 mg twice daily is reasonable to reduce the risk of bleeding as compared with triple therapy.</p> <p>NEW: New published data are available.</p>
IIb	B-R	<p>If triple therapy (oral anticoagulant, aspirin, and P2Y₁₂ inhibitor) is prescribed for patients with AF who are at increased risk of stroke (based on CHA₂DS₂-VASc risk score of 2 or greater) and who have undergone PCI with stenting (drug eluting or bare metal) for ACS, a transition to double therapy (oral anticoagulant and P2Y₁₂ inhibitor) at 4 to 6 weeks may be considered.</p> <p>NEW: New published data are available.</p>

AF Complicating ACS

Recommendations for AF Complicating ACS

COR	LOE	Recommendations
IIb	C	Administration of amiodarone or digoxin may be considered to slow a rapid ventricular response in patients with ACS and AF associated with severe LV dysfunction and HF or hemodynamic instability.
IIb	C	Administration of nondihydropyridine calcium antagonists may be considered to slow a rapid ventricular response in patients with ACS and AF only in the absence of significant HF or hemodynamic instability.

Device Detection of AF and Atrial Flutter (New)

Recommendations for Device Detection of AF and Atrial Flutter

CO R	LOE	Recommendations
I	B- NR	In patients with cardiac implantable electronic devices (pacemakers or implanted cardioverter-defibrillators), the presence of recorded atrial high-rate episodes (AHREs) should prompt further evaluation to document clinically relevant AF to guide treatment decisions.
Ia	B-R	In patients with cryptogenic stroke (i.e., stroke of unknown cause) in whom external ambulatory monitoring is inconclusive, implantation of a cardiac monitor (loop recorder) is reasonable to optimize detection of silent AF.

Weight Loss (New)

Recommendation for Weight Loss in Patients with AF		
CO R	LOE	Recommendation
I	B-R	<p>For overweight and obese patients with AF, weight loss, combined with risk factor modification, is recommended.</p> <p>NEW: New data demonstrate the beneficial effects of weight loss and risk factor modification on controlling AF.</p>